Neonatal Fc receptor – biology and therapeutics

Fcγ receptors as regulators of immune responses

Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · see citing works

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

Immune Thrombocytopenic Purpura

Cines, D. B., & Blanchette, V. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmra010501 · Cited by 1,366 · see citing works

Placental transport of immunoglobulin G

Simister, N. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00334-7 · Cited by 783 · see citing works

Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases

Cooper, G. S., Bynum, M. L. K., & Somers, E. C. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.008 · Cited by 760 · see citing works

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Howard, J. F., Bril, V., Vu, T., Karam, C., Perić, S., Margania, T., Murai, H., Bilińska, M. M., Shakarishvili, R., Śmiłowski, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00159-9 · Cited by 756 · see citing works

An Fc receptor structurally related to MHC class I antigens

Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729 · see citing works

The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · see citing works

Mechanisms of Autoantibody-Induced Pathology

Ludwig, R. J., Vanhoorelbeke, K., Leypoldt, F., Kaya, Z., Bieber, K., McLachlan, S. M., Komorowski, L., Luo, J., Cabral-Marques, O., Hammers, C. M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00603 · Cited by 475 · see citing works

Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

Ghetie, V. F., Hubbard, J. G., Kim, J., Tsen, M. F., Lee, Y., & Ward, E. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260327 · Cited by 469 · see citing works

THE TRANSMISSION OF IMMUNITY FROM MOTHER TO YOUNG AND THE CATABOLISM OF IMMUNOGLOBULINS

Brambell, F. W. R. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92190-8 · Cited by 463 · see citing works

The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs

Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S. B., Avanessian, L., Choi, E. Y., Shaffer, D. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3528 · Cited by 454 · see citing works

A Theoretical Model of γ-Globulin Catabolism

Brambell, F. W. R., Hemmings, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 451 · see citing works

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 433 · see citing works

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427 · see citing works

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407 · see citing works

A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus.

Story, C. M., Mikulska, J., & Simister, N. E. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2377 · Cited by 346 · see citing works

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of γ-globulin in humans

Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330 · see citing works

Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn

Ober, R. J., Martinez, C., Vaccaro, C., Zhou, J., & Ward, E. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2021 · Cited by 314 · see citing works

Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics

Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304 · see citing works

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Bril, V., Drużdż, A., Grosskreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vissing, J., Vu, T., Boehnlein, M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00077-7 · Cited by 295 · see citing works

The therapeutic age of the neonatal Fc receptor

Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288 · see citing works

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286 · see citing works

Dependence of antibody-mediated presentation of antigen on FcRn

Qiao, S., Kobayashi, K., Johansen, F., Sollid, L. M., Andersen, J. T., Milford, E. L., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801717105 · Cited by 281 · see citing works

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

Li, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24394 · Cited by 263 · see citing works

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · see citing works

Crystal Structure and Immunoglobulin G Binding Properties of the Human Major Histocompatibility Complex-Related Fc Receptor ,

West, A. P., & Björkman, P. J. (2000) · Biochemistry · doi:10.1021/bi000749m · Cited by 256 · see citing works

Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development

Klink, D. T., van Elburg, R. M., Schreurs, M. W. J., & van Well, G. T. J. (2008) · Clinical and Developmental Immunology · doi:10.1155/2008/271363 · Cited by 239 · see citing works

Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8 − CD11b + dendritic cells

Baker, K., Qiao, S., Kuo, T. T., Aveson, V. G., Platzer, B., Andersen, J. T., Sandlie, I., Chen, Z., de Haar, C. G., Lencer, W. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019037108 · Cited by 217 · see citing works

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1208 · Cited by 211 · see citing works

Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy

Wilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200 · see citing works

FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis

Vidarsson, G., Stemerding, A. M., Stapleton, N. M., Spliethoff, S. E., Janssen, H., Rebers, F. E. M., de Haas, M., & van de Winkel, J. G. J. (2006) · Blood · doi:10.1182/blood-2006-05-024539 · Cited by 198 · see citing works

The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease

Akilesh, S., Petkova, S. B., Sproule, T. J., Shaffer, D. J., Christianson, G. J., & Roopenian, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18838 · Cited by 197 · see citing works

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Newland, A. C., Sánchez‐González, B., Rejtő, L., Egyed, M., Romanyuk, N., Godar, M., Verschueren, K., Gandini, D., Ulrichts, P., Beauchamp, J., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25680 · Cited by 181 · see citing works

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Ling, L. E., Hillson, J., Tiessen, R. G., Bosje, T., van Iersel, M. P., Nix, D. J., Markowitz, L., Cilfone, N. A., Duffner, J. L., Streisand, J. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1276 · Cited by 160 · see citing works

Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant β 2 -microglobulin gene

Wani, M. A., Haynes, L. D., Kim, J., Bronson, C. L., Chaudhury, C., Mohanty, S., Waldmann, T. A., Robinson, J. M., & Anderson, C. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600548103 · Cited by 147 · see citing works

A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes.

Blumberg, R. S., Koss, T., Story, C. M., Barisani, D., Polischuk, J. E., Lipin, A., Pablo, L., Green, R. M., & Simister, N. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117934 · Cited by 147 · see citing works

Serum Immunoglobulins and Risk of Infection: How Low Can You Go?

Fürst, D. E. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.05.002 · Cited by 145 · see citing works

Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer

Baker, K., Räth, T., Flak, M. B., Arthur, J. C., Chen, Z., Glickman, J. N., Zlobec, I., Karamitopoulou, E., Stachler, M. D., Odze, R. D., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.003 · Cited by 142 · see citing works

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

Blumberg, L. J., Humphries, J. E., Jones, S. D., Pearce, L. B., Holgate, R., Hearn, A. R., Cheung, J., Mahmood, A., Tito, B. D., Graydon, J. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax9586 · Cited by 133 · see citing works

Impact of structural modifications of IgG antibodies on effector functions

Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 128 · see citing works

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

Allen, J. A., Lin, J., Basta, I. Z., Dysgaard, T., Eggers, C., Guptill, J. T., Gwathmey, K. G., Hewamadduma, C., Hofman, E. G., Hussain, Y., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00309-0 · Cited by 127 · see citing works

Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade

Liu, L., Garcia, A. M., Santoro, H., Zhang, Y., McDonnell, K. A., Dumont, J., & Bitonti, A. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5390 · Cited by 122 · see citing works

Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus B

Zhao, X., Zhang, G., Liu, S., Chen, X., Peng, R., Dai, L., Qu, X., Li, S., Song, H., Gao, Z., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.035 · Cited by 121 · see citing works

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors

Dalakas, M. C., & Spaeth, P. J. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286421997381 · Cited by 121 · see citing works

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Robak, T., Kaźmierczak, M., Jarque, I., Musteata, V., Treliński, J., Cooper, N., Kiessling, P. C., Massow, U., Woltering, F., Snipes, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002003 · Cited by 116 · see citing works

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Broome, C. M., McDonald, V., Miyakawa, Y., Carpenedo, M., Kuter, D. J., Al-Samkari, H. T., Bussel, J. B., Godar, M., Ayguasanosa, J., Beuf, K. D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01460-5 · Cited by 115 · see citing works

Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn

Moise, K. J., Ling, L. E., Oepkes, D., Tiblad, E., Verweij, E. J. T., Lopriore, E., Smoleniec, J., Sachs, U. J., Bein, G., Kilby, M. D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2314466 · Cited by 115 · see citing works

A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor α‐chain promoter

Sachs, U. J., Socher, I., Braeunlich, C. G., Kroll, H., Bein, G., & Santoso, S. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02408.x · Cited by 110 · see citing works

The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells

Gupta, S., Gach, J. S., Becerra, J. C., Phan, T. B., Pudney, J. A., Moldoveanu, Z., Joseph, S., Landucci, G., Supnet, M., Ping, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003776 · Cited by 102 · see citing works

Maternal immunity and antibodies to dengue virus promote infection and Zika virus–induced microcephaly in fetuses

Rathore, A. P. S., Saron, W. A. A., Lim, T., Jahan, N., & John, A. L. S. (2019) · Science Advances · doi:10.1126/sciadv.aav3208 · Cited by 99 · see citing works

FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies

Borghi, S., Bournazos, S., Thulin, N. K., Li, C., Gajewski, A., Sherwood, R., Zhang, S., Harris, E., Jagannathan, P., Wang, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004325117 · Cited by 95 · see citing works

Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine

Wallace, K., & Rees, A. R. (1980) · Biochemical Journal · doi:10.1042/bj1880009 · Cited by 84 · see citing works

β2-microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice

Christianson, G. J., Blankenburg, R. L., Duffy, T. M., Panka, D. J., Roths, J. B., Marshak‐Rothstein, A., & Roopenian, D. C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.12.4932 · Cited by 81 · see citing works

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor

Gouilleux‐Gruart, V., Chapel, H. M., Chevret, S., Lucas, M., Malphettes, M., Fieschi, C., Patel, S. Y., Boutboul, D., Marson, M.-N., Gérard, L., et al. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12002 · Cited by 76 · see citing works

Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis

Challa, D. K., Wang, X., Montoyo, H. P., Velmurugan, R., Ober, R. J., & Ward, E. S. (2019) · mAbs · doi:10.1080/19420862.2019.1602459 · Cited by 74 · see citing works

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

Billiet, T., Dreesen, E., Cleynen, I., Wollants, W.-J., Ferrante, M., Assche, G. V., Gils, A., & Vermeire, S. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.306 · Cited by 69 · see citing works

Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late‐onset Myasthenia Gravis

Liu, J., Wang, W., Xue, J., Zhao, C., You, H., Lu, J., & Gu, Y. (2009) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2009.00751.x · Cited by 68 · see citing works

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis

Guptill, J. T., Sleasman, J. W., Steeland, S., Sips, M., Gelinas, D. F., de Haard, H., Azar, A., & Winthrop, K. L. (2022) · Autoimmunity · doi:10.1080/08916934.2022.2104261 · Cited by 54 · see citing works

H 435‐containing immunoglobulin G 3 allotypes are transported efficiently across the human placenta: implications for alloantibody‐mediated diseases of the newborn

Einarsdottir, H., Ji, Y., Visser, R., Mo, C., Luo, G., Scherjon, S. A., van der Schoot, C. E., & Vidarsson, G. (2013) · Transfusion · doi:10.1111/trf.12334 · Cited by 52 · see citing works

The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement

Brinkhaus, M., Pannecoucke, E., van der Kooi, E. J., Bentlage, A. E. H., Derksen, N. I. L., Andries, J., Balbino, B., Sips, M., Ulrichts, P., Verheesen, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33764-1 · Cited by 51 · see citing works

FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity

Hubbard, J. J., Pyzik, M., Räth, T., Kozicky, L. K., Sand, K. M. K., Gandhi, A. K., Grevys, A., Foss, S., Menzies, S. C., Glickman, J. N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200359 · Cited by 47 · see citing works

β2-microglobulin–deficient Mice Are Resistant to Bullous Pemphigoid

Liu, Z., Roopenian, D. C., Zhou, X., Christianson, G. J., Diaz, L. A., Sedmak, D. D., & Anderson, C. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.777 · Cited by 43 · see citing works

FcRn mediates fast recycling of endocytosed albumin and IgG from early macropinosomes in primary macrophages

Toh, W. H., Louber, J., Mahmoud, I. S., Chia, J., Bass, G., Dower, S., Verhagen, A. M., & Gleeson, P. A. (2019) · Journal of Cell Science · doi:10.1242/jcs.235416 · Cited by 42 · see citing works

Hormonal control of intestinal Fc receptor gene expression and immunoglobulin transport in suckling rats.

Martín, M. G., Wu, S. V., & Walsh, J. H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116528 · Cited by 40 · see citing works

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

Yap, D. Y. H., Hai, J. J., Lee, P. C. H., Zhou, X., Lee, M., Zhang, Y., Wang, M., & Chen, X. (2021) · Clinical and Translational Science · doi:10.1111/cts.13019 · Cited by 38 · see citing works

Infused Fc-tagged β-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice

Grubb, J. H., Vogler, C. A., Tan, Y., Shah, G. N., MacRae, A. F., & Sly, W. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803715105 · Cited by 38 · see citing works

FcRn augments induction of tissue factor activity by IgG-containing immune complexes

Cines, D. B., Zaitsev, S. V., Rauova, L., Rux, A. H., Stepanova, V. V., Krishnaswamy, S., Sarkar, A., Kowalska, M. A., Zhao, G., Mast, A. E., et al. (2020) · Blood · doi:10.1182/blood.2019001133 · Cited by 37 · see citing works

VNTR2/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis

Su, S., Liu, Q., Zhang, X., Wen, X., Lei, L., Shen, F., Fan, Z., Duo, J., Lü, Y., Di, L., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420986747 · Cited by 29 · see citing works

Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin

Ma, G., Crowley, A. R., Heyndrickx, L., Rogiers, I., Parthoens, E., Van Santbergen, J., Ober, R. J., Bobkov, V., de Haard, H., Ulrichts, P., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176166 · Cited by 28 · see citing works

IgG Fab Glycans Hinder FcRn-Mediated Placental Transport

Volkov, M., Brinkhaus, M., van Schie, K. A., Bondt, A., Kissel, T., van der Kooi, E. J., Bentlage, A. E. H., Koeleman, C. A. M., de Taeye, S. W., Derksen, N. I. L., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200438 · Cited by 23 · see citing works

The neonatal Fc receptor is a cellular receptor for human astrovirus

Ingle, H., Molleston, J. M., Hall, P. D., Bui, D., Wang, L., Bhatt, K. D., Foster, L. R., Antia, A., Ding, S., Lee, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01855-y · Cited by 19 · see citing works

Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy

Mimoun, A., Bou-Jaoudeh, M., Delignat, S., Daventure, V., Reyes‐Ruiz, A., Lecerf, M., Azam, A., Noé, R., Peyron, I., Christophe, O. D., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.021 · Cited by 13 · see citing works

Exit pathways of therapeutic antibodies from the brain and retention strategies

Schellhammer, L., Beffinger, M., Salazar, U., Laman, J. D., Buch, T., & Berg, J. V. (2023) · iScience · doi:10.1016/j.isci.2023.108132 · Cited by 12 · see citing works

Fetal Congenital Heart Block Associated With Maternal Primary Systemic Lupus Erythematosus and Sjogren’s Syndrome

Khan, S., Anvekar, P., Lohana, P. J. D., Alam, M. S., & Ali, S. R. (2021) · Cureus · doi:10.7759/cureus.18036 · Cited by 5 · see citing works

Untitled work

(1999) · doi:10.1002/(sici)1521-4141(199909)29:09

Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease

Gharahdaghi, N., Yeh, P., Ceron‐Gutierrez, L., Griffin, H., Gordon, H., Jayamanne, C., Fracchia, A., Chong, A. Y.-Y., Walsh, A., Brain, O., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513654 · Cited by 21 · see citing works

Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?

Rossini, E., Leonardi, L., Morino, S., Antonini, G., & Fionda, L. (2025) · Brain Sciences · doi:10.3390/brainsci15090978 · Cited by 10 · see citing works

Diagnosis and Management of Fetal and Neonatal Alloimmune Thrombocytopenia: An Update 2025

Sachs, U. J., Bedei, I. A., Wienzek‐Lischka, S., Cooper, N., Ehrhardt, H., Axt-Fliedner, R., & Bein, G. (2025) · Transfusion Medicine and Hemotherapy · doi:10.1159/000547985 · Cited by 9 · see citing works

LYTACs and other extracellular targeted protein degradation TACnologies: guiding principles and potential clinical prospects

Niebel, B., Chen, W., Mukai, K., & Henry, C. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104601 · Cited by 9 · see citing works

Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study

Carlucci, P. M., Masson, M., Cuneo, B. F., Brandt, J. S., Worthing, A. B., Izmirly, P., Fraser, N., Sachan, N., Donofrio, M. T., Clancy, R. M., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.09.011 · Cited by 7 · see citing works

Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood–Brain Barrier

Guo, K., Cao, D., Marchese-Thomas, L. P., & Dong, Y. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00379 · Cited by 7 · see citing works

Anti–HPA-1a fetal-neonatal alloimmune thrombocytopenia: reframing diagnostics, pathophysiology, and management

Bussel, J. B., Hirshman, J. M., & Kapur, R. (2026) · Blood · doi:10.1182/blood.2025032550 · Cited by 6 · see citing works

Defective lymphangiogenesis and iron removal after hemarthrosis in factor VIII-deficient mice are rectified with therapeutic factor VIII administration—implications for joint health

Joseph, B. C., Pablo-Moreno, J. A. D., Falah, N., Cacho, M. L., & von Drygalski, A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.08.016 · Cited by 5 · see citing works

Increased frequency of autism by previous diagnosis and screening in children with fetal-neonatal alloimmune thrombocytopenia with and without an intracranial hemorrhage

McFarland, E. A., Knightly, K. A., Haar, E. V., McKelvy, M. H., Palmer, T. D., Volpe, S. V., Corke, S., & Bussel, J. B. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.06.052 · Cited by 4 · see citing works

Red blood cell alloimmunization and pregnancy: Diagnosis and management

Valentini, B., Zegarra, R. R., Ghi, T., & Dall’Asta, A. (2025) · Pregnancy · doi:10.1002/pmf2.70085 · Cited by 3 · see citing works

The conserved human astrovirus-receptor interface reveals a targetable vulnerability for antiviral development

Wang, W., Xu, Y. H., Li, Z., Liu, D., Ma, K., Wang, R., Chen, R., Shu, B., Sun, X., Liu, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70465-5 · Cited by 3 · see citing works

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions

Bril, V., Drużdż, A., Großkreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vu, T., Boehnlein, M., Grimson, F., et al. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261458532 · Cited by 3 · see citing works

Platelet Fc gamma RIIA: time to go beyond the unknown

Andrianova, I. A., Thubthed, R., & Denorme, F. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000881 · Cited by 3 · see citing works

Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell–Mediated Autoimmune Diseases

Rujitharanawong, C., Werth, V. P., & Payne, A. S. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.09.373 · Cited by 2 · see citing works

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐ AChR Antibody‐Positive Myasthenia Gravis: FGF ‐19 as a Novel Biomarker

Luo, T., Peng, D., Zhang, Z., Yang, M., Guo, X., Ma, T., Huang, X., Xu, M., Fu, L., & Zhang, Y. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70261 · Cited by 2 · see citing works

New developments and future directions in the management of systemic lupus erythematosus

Kirou, K. A., Kirou, R. A., & Flouda, S. (2026) · Current Opinion in Immunology · doi:10.1016/j.coi.2026.102774 · Cited by 2 · see citing works

Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain–Barré Syndrome?

Kang, E., Yünce, M., & Baykara, Y. (2026) · Journal of Clinical Apheresis · doi:10.1002/jca.70148 · Cited by 2 · see citing works

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue

Zantek, N. D., Alquist, C. R., Hofmann, J. C., Klingel, R., Levenbrown, Y., Onwuemene, O. A., Patidar, G. K., Patriquin, C. J., Raval, J. S., Sanchez, A. P., et al. (2026) · Journal of Clinical Apheresis · doi:10.1002/jca.70141 · Cited by 2 · see citing works

FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia

Sandhu, M., & Murakhovskaya, I. (2025) · Antibodies · doi:10.3390/antib14030065 · Cited by 1 · see citing works

Adding the FcRn antagonist efgartigimod for the prevention of IgG ‐mediated complications in the peri‐transplant period

COOPER, D. L., Verceles, J. A., Kheradmand, T., Paroder, M., Lombardo, A., de Castro, A., Browne, R., Konopleva, M., Moavero, B., Goldfinger, M., et al. (2025) · Transfusion · doi:10.1111/trf.18374 · Cited by 1 · see citing works

A real-time imaging approach to quantify dendritic cell internalization for immunogenicity risk assessment of biotherapeutics

Yin, Z., Tran, P., Guerrero, J., Low, J., Xie, Q. S., & Peng, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1632302 · Cited by 1 · see citing works

Immune Thrombocytopenia (ITP)

Bussel, J. B., Peko, G., & Cooper, N. (2025) · Springer eBooks · doi:10.1007/978-3-031-96348-3_3 · Cited by 1 · see citing works

Euthyroidism and Long-Term Remission of Graves’ Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report

Kahaly, G., Wolf, J., Luffy, M., Albert, K., & Macias, W. L. (2026) · Thyroid · doi:10.1177/10507256261423190 · Cited by 1 · see citing works

Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography

Kiyoshi, M., Suzuki, T., Inoue, N., Otake, R., Yumoto, T., Hirono, L., Terao, Y., Shibata, H., Ide, T., Nagatoishi, S., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09789-3 · Cited by 1 · see citing works

Immobilized recombinant FcγRIIIa and FcRn receptors as a tool for characterization of human IgG antibodies

Dončević, L., Friganović, T., Grbčić, P., Filipović, M., Borosak, I., Habazin, S., Lauc, G., Müller, E., & Josić, D. (2026) · Journal of Chromatography B · doi:10.1016/j.jchromb.2026.125107 · Cited by 1 · see citing works

Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases

Liang, P., Cai, S., Sun, W. J., & Dong, L. (2026) · Inflammation Research · doi:10.1007/s00011-026-02279-6 · Cited by 1 · see citing works

Cleavage-activatable antibody-photosensitizer conjugate enables tumor-selective photodynamic activation and immunogenic cell death

Yoo, Y.-J., Lee, S. S., Kim, H., & Choi, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115212 · Cited by 1 · see citing works

The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro

Sirina, J., D'Hooghe, L. E., Singhvi-Hanns, L. A., Cole, S. L., Shock, A., Holliday, N. D., & Stoddart, L. A. (2026) · Cellular Immunology · doi:10.1016/j.cellimm.2026.105128

Neonatal Fc Receptor — Biology and Therapeutics

Bussel, J. B., Cines, D. B., & Blumberg, R. S. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2507104

Molecular determinants of antibody-mediated priming to enhance detection of ctDNAPreprint

Tabrizi, S., Sullivan, C., Chakraborty, K., Martin-Alonso, C., An, Z., Gao, L., Kim, D. M., Patel, S. K., Blewett, T., Rhoades, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.701975

Structure-guided design of a targeted autoantibody degrader for neurologic diseasePreprint

Zimanyi, M., Dayao, M. T., Asencor, A. I., Kondapavulur, S., Asaki, J., McCutcheon, K. M., Dabaco, C., Bodansky, A., Craik, C. S., Pleasure, S. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.01.703132

Italian recommendations for the diagnosis and treatment of myasthenia gravis

Fionda, L., Alboini, P. E., Antozzi, C. G., Bonifati, D. M., Damato, V., Habetswallner, F., Inghilleri, M., Iorio, R., Liguori, R., Tassoni, M. M., et al. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08964-y

Monoclonal Antibodies in Pregnancy of Patients with Systemic Lupus Erythematosus: Friend or Foe? A Case Report of a Patient with Multiple Pregnancies

Orlandi, C., Tincani, A., Fredi, M., Andréoli, L., Crisafulli, F., Moschetti, L., Nalli, C., Lazzaroni, M. G., Taglietti, M., Filippini, M., et al. (2026) · Antibodies · doi:10.3390/antib15020032

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients

Martínez-Toledo, C., Meseguer, M. J., Molina-Alejandre, M., Calvo, V., Collazo-Lorduy, A., Sierra‐Rodero, B., Blanco, M., Cutillas, M. M., Gil-González, Á., Gutiérrez-Escobedo, J. M., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108232

The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review

Hadzic, B., Vasbinder, E. C., Lek, R., Cabezas, M. C., & Braunstahl, G. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s554138

B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis

Solomon, J. L., Dubbaka, A., Srivastava, A., Belilos, E., Leon, J. D., Carsons, S. E., & Reiss, A. B. (2026) · Life · doi:10.3390/life16060923

Hypoproteinemia and Hypogammaglobulinemia Due to a Homozygous FCGRT Mutation

Ala, A. S., Lo, B., Ozen, A. O., İşlek, A., & Tümgör, G. (2026) · Journal of Clinical Immunology · doi:10.1007/s10875-026-02032-y

Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering

Li, S. N., Gao, Y. N., Zhu, C.-G., & Li, J. (2026) · Drugs · doi:10.1007/s40265-026-02348-4

Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment

Wainwright, B. J., Gutowski, E. D., Saxena, A., Carlucci, P. M., Cuneo, B. F., Izmirly, P., & Buyon, J. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33957-8.00052-4

Systemic Inflammation as a Modulator of FcRn-dependent IgG Pharmacokinetics: Implications for Broadly Neutralising Antibody Efficacy in HIV Prevention

Khumalo, A., Pillay, S., Mohan, J., Mahomed, S., & Archary, D. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00791-2

Factor XI Inhibition: Adult Evidence and Paediatric Considerations

Holzhauer, S., & Male, C. (2026) · Hämostaseologie · doi:10.1055/a-2918-8066

A Man with Refractory Bulbar Symptoms That Require Frequent Plasmapheresis

Pervin, S., & Wolfe, G. I. (2026) · Springer eBooks · doi:10.1007/978-3-032-28877-6_14

Fetal and Neonatal Alloimmune Thrombocytopenia in the Middle East: A Confirmed Case Highlighting Immunogenetic Diversity and Evidence-Based Neonatal Management

Mohamad, H. H., Soudan, R., Makkiyah, R., Abdalla, S., Haroon, S., George, J., & Abdalla, A. (2026) · Cureus · doi:10.7759/cureus.114213

Single‐Nucleus and Multiomics Profiling of Epicardial Adipose Tissue in Atrial Fibrillation Reveals Novel Mechanisms and Translational Biomarkers

Huang, S., Yang, Z., Zhong, X., Li, C., Zhen, J., Cai, X., Gao, Y., Liang, R., Wu, H., Wang, Z., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049221

Beyond Hemolysis and Transfusion: The Untold Story of Blood Groups in Neonatal Disease

Sokou, R., Palioura, A. E., Lianou, A., Aggelopoulou, S., Tsantes, A. G., Bonovas, S., Mougiou, V., Ilidromiti, Z., Boutsikou, Τ., Tsantes, A. Ε., et al. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2943-5876

Equitable access to monoclonal antibodies targeting parasites

Thahir, S., Bowman, N. M., Crompton, P. D., Seder, R. A., Kayentao, K., & Tran, T. M. (2026) · Trends in Parasitology · doi:10.1016/j.pt.2026.08.002

Targeted therapies in systemic lupus erythematosus: mechanistic insights and clinical evidence from phase II and III trials

Abrantes, J. F., Dueñas-Ochoa, M., Meidan, R., & Isenberg, D. A. (2026) · Frontiers in Lupus · doi:10.3389/flupu.2026.1829480

Treatment Updates for Type 1 Autoimmune Pancreatitis and IgG4-Related Diseases

Hernandez-Barco, Y. G., & Perugino, C. A. (2026) · SMART-MD journal of precision medicine. · doi:10.69734/8p34ma30

Efficacy and safety of acute-phase immunotherapy for adult autoimmune encephalitis: a systematic review and network meta-analysis

邓彦, Cai, Y., Yang, X., Xu, L., Chen, Y., Na, L., & Di, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807436

Bispecific and Multispecific Antibodies

Mandane, B., & Crintea, A. N. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch012

A Case of Acute‐Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy Occurring During a Flare of Chronic Immune Thrombocytopenia

Kobayashi, G., Katsumata, M., Imai, M., Shimazu, Y., Inoue, K., Shirai, T., & Hagihara, M. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70180

Antibody and Related Biologic Therapeutics in Ocular Diseases: Molecular Targets, Clinical Applications, and Next-Generation Delivery Strategies

Mwale, P. F., Yen, T., Hsiao, G., Jan, J., Darmanto, A. G., Yang, C., Chen, Y.-H., & Cheng, Y. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48111144

Fc receptors on isolated neonatal rat enterocytes

MACKENZIE, N., Morris, B., & MORRIS, R. (1980) · Cell Biology International Reports · doi:10.1016/0309-1651(80)90138-1 · Cited by 4 · see citing works

Crystal structure of the complex of rat neonatal Fc receptor with Fc

(1995) · Trends in Genetics · doi:10.1016/0168-9525(95)90005-5 · Cited by 382 · see citing works

Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus

(2019) · Case Medical Research · doi:10.31525/ct1-nct03896373

The biology and pathology of Fc receptors

Sándor, M., & Lynch, R. G. (1993) · Journal of Clinical Immunology · doi:10.1007/bf00919382 · Cited by 25 · see citing works

Targeting the Neonatal Fc Receptor, FcRn, to Treat Autoimmunity and Elucidation of Sites of FcRn Function

Challa, D. K. (2016)